Use of liposomal amphotericin B in critically ill patients: A retrospective, multicenter, clinical study

Journal of Chemotherapy

Volumn 21, Issue 3, 2009, Pages 330-337

  Álvarez Lerma, Francisco ^a   Mariscal, F ^b   Quintana, E ^c   Rialp, G ^d   Diaz Reganon J ^e   Perez M J ^f   Alvarez Sanchez B ^g   Ausin Aoiz I ^h  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL SON LLÀTZER   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^h Gilead Sciences   (Spain)

Author keywords

Critically ill patient; ICU; Invasive fungal infections; Liposomal amphotericin B

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CREATININE; FLUCONAZOLE; VORICONAZOLE;

ADULT; ARTICLE; ASPERGILLUS; CANDIDA ALBICANS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FEVER; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPOKALEMIA; INVASIVE CANDIDIASIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PATHOGENESIS; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 68349101184     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.3.330     Document Type: Article

References (21)

1. Alvarez-Lerma F, Nolla J, Palomar M, León MA. Treatment approach for fungal infections in critically ill patients admitted to intensive care units: results of a multicenter survey. [Article in Spanish]. Enferm Infecc Microbiol Clin 2003; 21: 83-88.
2. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Clin Infect Dis 2003; 37: 1172-1177.
3. Ostrosky-Zeichner L. Prophylaxis or preemptive therapy of invasive candidiasis in the intensive care unit? Crit Care Med 2004; 32: 2552-2553.
4. Gavaldà J, Ruiz I. Guidelines for the treatment of invasive fungal infection. Invasive fungal infection by Candida spp. Invasive Fungal Infection Study Group (MICOMED) and Infection in Transplantation Study Group (GESITRA) of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC). [Article in Spanish]. Enferm Infecc Microbiol Clin 2003; 21: 498-508.
5. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189.
6. Garnacho-Montero J, León Gil C, Almirante B, Alvarez Lerma F, Cuenca Estrella M, García Rodríguez JA, et al. Recomendaciones terapéuticas en el paciente critico no neutropénico. Conferencia de Consenso. Conclusiones. Med Intensiva 2005 (Suppl 3): 43-52.
7. León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730-737. (Pubitemid 43308263)
8. Ruiz-Santana S, Leon C, Saavedra P, Almirante B. The "Seville score": a new preemptive antifungal therapy approach for candida colonization in non-neutropenic critically ill patients. Crit Care Med 2004; 32 (Suppl): A11.
9. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26: 271-276. (Pubitemid 46572022)
10. Álvarez-Lerma F, Palomar M, León C, Olaechea P, Cerda E, Bermejo B. Indicaciones para el tratamiento antifúngico en pacientes ingresados en UCI. Enferm Infecc Microbiol Clin 2004; 22: 279-285. (Pubitemid 38756627)
11. Grupo de Trabajo de Enfermedades Infecciosas de la SEMICYUC. Estudio Nacional de Vigilancia de Infección Nosocomial en Servicios de Medicina intensiva. Report 2006.
12. Álvarez-Lerma F, Nicolás-Arfelis JM, Rodríguez- Borregán JC, Díaz-Regañón J, SA-Borges M, García-López F, Allepuz-Palau A. Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients. J Chemother 2005; 17: 417-427.
13. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
14. Ascioglu S, Rex JH, de Pauw B, Bennet JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14. (Pubitemid 33152659)
15. Moran JL, Solomon PJ, Williams PJ. Assessment of outcome over a 10-year period of patients admitted a multidisciplinary adult intensive care unit with haematological and solid tumours. Anaesth Intensive Care 2005; 33: 26-35.
16. Jordà-Marcos R, Alvarez-Lerma F, Jurado M, Palomar M, Nolla-Salas J, León C, et al. Risk factors for candidaemia in critically ill patients: a prospective surveillance study. Mycoses 2007; 50: 302-310. (Pubitemid 46920274)
17. Bougnoux ME, Kac G, Aegerter P, d'Enfert C, Fagon JY. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med 2007; 34: 292-299.
18. Álvarez Lerma F, Palomar M, Olaechea P, Otal JJ, Insausti J, Cerdá E. National Study of Control of Nosocomial Infection in Intensive Care Units. Evolutive report of the years 2003-2005. [Article in Spanish]. Med Intensiva 2007; 31: 6-17.
19. Álvarez-Lerma F, Palomar M, León C, Olaechea P, Cerdá E, Bermejo B. Fungal colonization and/or infection in intensive care units. Multicenter study of 1,562 patients. [Article in Spanish]. Med Clin (Barc) 2003; 121: 161-166. (Pubitemid 36974771)
20. Frothinghan R. Lipid formulations of amphotericin B for empiric treatment of fever and neutropenia. Clin Infect Dis 2002; 35: 896-897.
21. Bellmann R, Egger P, Wiedermann CJ. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence. Clin Infec Dis 2003; 36: 1500-1501. (Pubitemid 36702889)